Qrons (QRON) Total Stockholders Equity: $-0.45 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Qrons Total Stockholders Equity?

Qrons QRON Total Stockholders Equity is $-0.45 Mil as of Dec. 2024.

Qrons's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-0.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Qrons's Book Value per Share for the quarter that ended in Dec. 2024 was $-0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Qrons's Debt-to-Equity for the quarter that ended in Dec. 2024 was -0.67.

Qrons  (OTCPK:QRON) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Qrons's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-0.445-0)/17.600
=-0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Qrons's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.286 + 0.01) / -0.445
=-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qrons Total Stockholders Equity Related Terms

Qrons Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Qrons's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qrons Total Stockholders Equity Chart

Qrons Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only -0.69 -1.10 -1.28 -1.49 -0.45

Qrons Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 -1.47 -1.23 -1.26 -0.45
What does a Total Stockholders Equity of $-0.45 Mil mean?
Qrons (QRON) has a Total Stockholders Equity of $-0.45 Mil as of Dec. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Qrons and its competitors.
Is Qrons' Total Stockholders Equity too high?
Qrons' current Total Stockholders Equity is $-0.45 Mil.
How does Qrons' Total Stockholders Equity compare to GBLX and ENDV?
Qrons' Total Stockholders Equity of $-0.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Qrons and its competitors. Qrons's current Total Stockholders Equity is $-0.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qrons stock overvalued right now?
Qrons (QRON) has a current Total Stockholders Equity of $-0.45 Mil. The current Total Stockholders Equity is $-0.45 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Qrons (QRON), the current Total Stockholders Equity is $-0.45 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qrons Business Description

Address 611 N. Brand Boulevard, Suite 1300, Glendale, CA, USA, 91203
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.